Internal Medicine, Allergy & Immunology · Houston, TX
NPI
1629084397
Since 2006
Specialty
Internal Medicine, Allergy & Immunology
Code 207RA0201X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
12000 Richmond Ave, Suite 175
Houston, TX, 77082
Phone (713) 790-0900
Groups this clinician bills Medicare through
Medicare paid, 2024
$231K
29,516 services
Medicare patients, 2024
151
Average age 75
Drug cost, 2024
$3.0M
1,181 prescriptions
Company payments, 2025
$2,092
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Julie Y Patel was code J0897 (injection, denosumab, 1 mg), 1,620 times for 18 patients. In total Julie Y Patel billed 29,516 services in 35 codes, and Medicare paid $231K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,620 | 18 | $20.52 | $33K |
| 99214 Office E&M - Established | Office | 253 | 127 | $91.17 | $23K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 185 | 94 | $12.19 | $2,254 |
| 96401 Chemotherapy Administration | Office | 180 | 25 | $52.26 | $9,407 |
| 99442 Telephone Services | Office | 73 | 46 | $65.69 | $4,795 |
| 36415 Venipuncture Blood Collection | Office | 45 | 34 | $8.65 | $389 |
| 99204 Office E&M - New | Office | 22 | 22 | $117.77 | $2,591 |
By year: 2022 $433K for 46,384 services; 2023 $360K for 47,549 services; 2024 $231K for 29,516 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 45 | 34 | $8.65 | $389 |
Medicare prescription drug claims, 2024
In 2024, the drug Julie Y Patel prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 120 prescriptions and refills. In total Julie Y Patel wrote 1,181 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 120 | 273 | 38 | $3,908 |
| Prednisone Generic | 114 | 163 | 36 | $764 |
| Hydroxychloroquine Sulfate Generic | 94 | 258 | 35 | $3,177 |
| Humira(Cf) Pen Adalimumab | 54 | 59 | Under 11 | $395K |
| Leflunomide Generic | 50 | 112 | 15 | $2,549 |
| Celecoxib Generic | 38 | 53 | 16 | $668 |
| Levocetirizine Dihydrochloride Generic | 29 | 55 | Under 11 | $325 |
| Tramadol Hcl Generic | 27 | 27 | Under 11 | $196 |
| Pregabalin Generic | 25 | 31 | Under 11 | $532 |
| Methylprednisolone Generic | 21 | 33 | Under 11 | $623 |
| Allopurinol Generic | 21 | 52 | Under 11 | $235 |
| Orencia Clickject Abatacept | 20 | 20 | Under 11 | $113K |
| Montelukast Sodium Generic | 20 | 34 | Under 11 | $212 |
| Haegarda C1 Esterase Inhibitor | 20 | 20 | Under 11 | $838K |
| Folic Acid Generic | 19 | 47 | Under 11 | $176 |
Brand drugs: 302 claims; generic drugs: 879 claims; opioid claims: 34.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Julie Y Patel $2,092 ($2,092 in general payments such as food, travel and fees) from 28 companies. The largest payer was Amgen Inc. with $386.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 8 | $386 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $171 |
| UCB, Inc. UCB.BR | 6 | $143 |
| GlaxoSmithKline, LLC. GSK | 5 | $143 |
| Galderma Laboratories, L.P. GALD.SW | 1 | $132 |
| Organon LLC OGN | 1 | $108 |
| CSL Behring CSL.AX | 5 | $104 |
| Pharming Healthcare, Inc. | 5 | $99.68 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $86.92 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 4 | $82.35 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.